Tandem Diabetes Care (TNDM) EBT Margin (2013 - 2026)
Tandem Diabetes Care (TNDM) posted EBT Margin of 8.05% for Q1 2026, down 594.38% on a QoQ basis from 1.63% in Q4 2025, and up 4404.0% year-over-year from 0.18% in Q1 2025.
Tandem Diabetes Care (TNDM) EBT Margin (2013 - 2026) Analysis & Trends
Tandem Diabetes Care's EBT Margin history runs 14 years deep, the most recent figure standing at 8.05% for Q1 2026.
- Quarterly EBT Margin rose 4404.0% year-over-year to 8.05% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 9.54% (up 821.0% YoY) and the FY2025 annual result came in at 19.74%, down 997.0% from the prior year.
- EBT Margin was 8.05% for Q1 2026 at Tandem Diabetes Care, down from 1.63% in the prior quarter.
- Across five years, EBT Margin topped out at 1.63% in Q4 2025 and bottomed at 72.97% in Q1 2023.
- A 5-year average of 17.96% and a median of 13.4% in 2024 frame the typical range for EBT Margin.
- Annual changes were most pronounced in 2023 — EBT Margin tumbled 6363 bps — and 2024, when it jumped 5235 bps.
- Tandem Diabetes Care's EBT Margin stood at 7.33% in 2022, then tumbled by 117 bps to 15.91% in 2023, then soared by 100 bps to 0.01% in 2024, then soared by 28663 bps to 1.63% in 2025, then slumped by 594 bps to 8.05% in 2026.
- Business Quant data shows TNDM's EBT Margin at 8.05% in Q1 2026, 1.63% in Q4 2025, and 10.09% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | 12.98% |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | 14.12% |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | 18.70% |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | 22.33% |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | 27.84% |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | 22.61% |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | 4.87% |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 9.84% |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | Tandem Diabetes Care | 1.16 Bn | 587.46 Mn | 136.79 Mn | -8.05% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -8.05% |
| Dec 31, 2025 | 1.63% |
| Sep 30, 2025 | -10.09% |
| Jun 30, 2025 | -23.98% |
| Mar 31, 2025 | -52.09% |
| Dec 31, 2024 | 0.01% |
| Sep 30, 2024 | -9.27% |
| Jun 30, 2024 | -13.40% |
| Mar 31, 2024 | -20.62% |
| Dec 31, 2023 | -15.91% |
| Sep 30, 2023 | -16.55% |
| Jun 30, 2023 | -17.66% |
| Mar 31, 2023 | -72.97% |
| Dec 31, 2022 | -7.33% |
| Sep 30, 2022 | -23.15% |
| Jun 30, 2022 | -6.47% |
| Mar 31, 2022 | -9.35% |
| Dec 31, 2021 | 5.29% |
| Sep 30, 2021 | 3.23% |
| Jun 30, 2021 | 2.38% |